Literature DB >> 29099609

Dual Bronchodilation Response by Exacerbation History and Eosinophilia in the FLAME Study.

Alberto Papi1, Konstantinos Kostikas2, Jadwiga A Wedzicha3, Claus F Vogelmeier4, Nicolas Roche5, Steven Shen6, Donald Banerji6, Robert Fogel6, Francesco Patalano2, Kenneth R Chapman7,8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29099609     DOI： 10.1164/rccm.201709-1822LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  9 in total

1.  Predictors of Asthma/COPD Overlap in FDNY Firefighters With World Trade Center Dust Exposure: A Longitudinal Study.

Authors:  Ankura Singh; Charles Liu; Barbara Putman; Rachel Zeig-Owens; Charles B Hall; Theresa Schwartz; Mayris P Webber; Hillel W Cohen; Kenneth I Berger; Anna Nolan; David J Prezant; Michael D Weiden
Journal:  Chest       Date:  2018-07-17       Impact factor: 9.410

2.  Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials.

Authors:  Dave Singh; Jadwiga A Wedzicha; Salman Siddiqui; Alberto de la Hoz; Wenqiong Xue; Helgo Magnussen; Marc Miravitlles; James D Chalmers; Peter M A Calverley
Journal:  Respir Res       Date:  2020-09-17

3.  Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study.

Authors:  Antonio R Anzueto; Konstantinos Kostikas; Karen Mezzi; Steven Shen; Michael Larbig; Francesco Patalano; Robert Fogel; Donald Banerji; Jadwiga A Wedzicha
Journal:  Respir Res       Date:  2018-06-20

4.  Are blood eosinophils a prime-time biomarker for COPD management decisions?

Authors:  Ioanna Tsiligianni; Alan G Kaplan
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-06-12

5.  Real-life effectiveness of indacaterol-glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study.

Authors:  Alan Kaplan; Kenneth R Chapman; Syed M Anees; Irvin Mayers; Driss Rochdi; Michel Djandji; David Préfontaine; Andrew McIvor
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-01-18

Review 6.  A Framework For Step Down Or Therapeutic Re-Organization For Withdrawal Of Inhaled Corticosteroids In Selected Patients With COPD: A Proposal For COPD Management.

Authors:  Claudio Micheletto; Fulvio Braido; Marco Contoli; Fabiano Di Marco; Pierachille Santus
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-09-23

Review 7.  Overuse of inhaled corticosteroids in COPD: five questions for withdrawal in daily practice.

Authors:  Didier Cataldo; Eric Derom; Giuseppe Liistro; Eric Marchand; Vincent Ninane; Rudi Peché; Hans Slabbynck; Walter Vincken; Wim Janssens
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-07-05

8.  The effect of exacerbation history on outcomes in the IMPACT trial.

Authors:  David M G Halpin; Mark T Dransfield; MeiLan K Han; C Elaine Jones; Sally Kilbride; Peter Lange; David A Lipson; David A Lomas; Fernando J Martinez; Steve Pascoe; Dave Singh; Robert Wise; Gerard J Criner
Journal:  Eur Respir J       Date:  2020-05-21       Impact factor: 16.671

Review 9.  Dual Bronchodilator in the Era of Triple Therapy.

Authors:  Andriana I Papaioannou; Stelios Loukides; Petros Bakakos; Epameinondas N Kosmas; Nikoletta Rovina; Paschalis Steiropoulos; Evangellia Fouka; Georgios Hillas; Georgios Patentalakis; Marousa Kouvela; Nikos Tzanakis
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-10-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.